5 January 2023
ArthroSave raises new investment round to battle severe knee osteoarthritis
Patients with knee osteoarthritis have a damaged knee joint and suffer from persistent pain every day. In Europe alone over 2.2 million patients are affected by knee osteoarthritis and prevalence is rising dramatically, due to rising obesity rates and aging population.
Karianne Lindenhovius, CEO and co-founder of ArthroSave, explains: “ArthroSave has developed the KneeReviver enabling knee joint distraction as a joint preserving solution. Knee joint distraction with the KneeReviver is a temporary treatment that unloads the knee joint for six weeks. This results in relief of pain and improvement of function. Due to regeneration of the joint, the original knee joint will be preserved. This will postpone the knee placement surgery for 10 more years and will prevent complex revision surgery later in life.”
16 August 2022
ArthroSave attends the AGA congress in Vienna
The AGA is Europe’s largest society for arthroscopy. The “AGA – SOCIETY FOR ARTHROSCOPY AND JOINT SURGERY” is Europe’s largest specialist society for arthroscopy with currently more than 5,600 members.
Founded in Zurich in 1983 as the AGA German-speaking working group for arthroscopy as an association of visionary, German-speaking surgeons and orthopedists with the aim of establishing and further developing arthroscopy as a new, minimally invasive procedure.
This year, you are most welcome at our stand nr.04. The event will be in Vienna from September 15-17, 2022.
17 May 2022
ArthroSave in LoaD consortium Erasmus MC
Osteoarthritis is a painful, debilitating joint disease that affects millions of people and for which there is no curative treatment. Patients are encouraged to keep moving, but the optimal joint load for the individual patient is not known. In the LoaD project, researchers from medical centers, technical universities, universities of applied sciences and companies are working together to investigate what a healthy load is for a patient with knee osteoarthritis and how patients can be guided to exercise healthly.
Budget: 10 million euros co-funded by companies and social partners such as sports associations and patient associations.
The consortium is led by Erasmus MC and consists of over 30 partner organisations.
17 May 2022
ArthroSave attends EIT Health Summit in the Karolinska Institutet in Stockholm
ArthroSave will attend the EIT Health Summit in Stockholm at May 24-25 at the Karolinska Institutet. Meet ArthroSave as promising European start-up competing in the Catapult competition and don’t miss the opportunity to learn about our joint preserving treatment.
We are looking for ambitious hospitals and orthopedic surgeons and investors. Do we meet you at our poster presentation?
17 May 2022
MRI shows cartilage thickness increase up to 10 years after distraction treatment
Knee joint distraction (KJD) has been shown to result in long-term clinical improvement and short- term cartilage restoration in young OA patients. The objective of the current study was to evaluate MRI cartilage thickness up to 10 years after KJD treatment, using a 3D surface-based approach.
Conclusion. KJD results in significant short- and long-term cartilage regeneration, up to 10 years post-treatment.
Mylène Jansen, Simon C.Mastbergen, James W.Mackay, Tom D.Turmezei, Floris Lafeber.
13 May 2022
Our first Webinar
Last month ArthroSave and MedScaler successfully hosted a webinar titled “Postponing the need for total knee replacement: The benefits of Knee Joint Distraction”. The presentations by Dr. Peter van Roermund and Dr. Ronald van Heerwaarden give in depth insight in the advantages of KneeReviver. Especially Dr. van Heerwaarden who is an independant orthopedic surgeon with a focus on joint preserving surgery, has a very clear opinion about KneeReviver. Curious which insight were shared? Click button below.
4 April 2022
Dobermann dog is running again after knee distraction. Michelle congratulations
On March 31, Michelle Teunissen obtained her doctorate with her dissertation ‘A joint effort’. In addition to her animal experimental research into knee distraction, Michelle has also successfully applied this treatment for the first time in a dog (Dobermann) with end-stage osteoarthritis. The dog was actually going to be put to sleep. Now -two years later- he runs and plays through the meadows.
Michelle’s research reveals important new insights into the tissue repair process in knee distraction, which helps us at ArthroSave to optimize treatment. For a long time it was thought that osteoarthritis cannot be cured. With this research, Michelle shows how knee distraction develops cartilage and bone growth.
Dissertation: A joint effort: How dogs contribute and benefit from the “One Medicine” approach to osteoarthritis.
If you click on the read more button you can use the passcode:156723 to read the full thesis.
Picture from left to right: Dr.Peter van Roermund, Ir.Karianne Lindenhovius, Dr.Michelle Teunissen, Dr. Simon Mastbergen, Prof. Marianna Tryfonidou
26 January 2022
ArthroSave is the only Dutch medtech company reaching the EIT Health Catapult Final
Twenty-one start-ups from across Europe have secured their places at the EIT Health Catapult final. ArthroSave is one of them! The finalists represent the most promising European start-ups across biotech, medtech and digital health.
Each team will now pitch their solution to the EIT Health network at the EIT Health Summit, due to take place May 24th – 25th 2022, in Stockholm, Sweden. The EIT Health network is one of the largest healthcare communities worldwide including over 150 leading healthcare organisations.
Learn more about the finalists here:
12 November 2021
Great news! We’ve been selected as a semifinalist in the EIT Health Catapult competition
ArthroSave has been selected as a semifinalist in the EIT Health Catapult competition. Discover more about innovative projects for the healthcare industry. Don’t miss out on the semifinals event on 1-3 December 2021!
By taking part in the EIT Health Catapult, successful start-ups receive high-quality, bespoke training in business modelling and planning, investment deal negotiation and specialised pitch preparation, while gaining access to Europe’s top healthcare experts and investors. The start-ups receive intensive training as they build their credibility and visibility through pan-European exposure.
Finalists are showcased at the EIT Health Summit as they go head-to-head for their share of the €210,000 investment prize fund with the Audience Award Winner displayed on the New York Nasdaq Tower.
19 October 2021
Great news! We’ve been selected for the first edition of Pole Position
We are so thrilled to have been selected for the first edition of Pole Position – an initiative tailored for ambitious deeptech companies who want to fasten their growth. This initiative will help us scale more efficiently by providing access to the best experts and network.
11 October 2021
From Mayo Clinic USA, Dutch professor of regenerative medicine Daniël Saris makes a remarkably optimistic sound
October 9, 2021- Hoop voor versleten knieën Volkskrant.
Osteoarthritis mainly affects the knees, followed at some distance by hips. A cure seems far away. Danish researchers drew a gloomy conclusion a few years ago in Science Translational Medicine: Once cartilage is damaged, forget it. There is no treatment, only symptom treatment is possible. However…..
From Rochester USA, the Dutch professor of Regenerative Medicine Daniël Saris makes a remarkably optimistic sound.
It is indeed possible to grow cartilage, he says. He is doing research about a technique for local cartilage defects first at the UMC Utrecht, now at Mayo Clinic USA. For patients with severe knee osteoarthritis in a late stage of the disease knee joint distraction is an option. Saris sees a solution for a growing group of patients…
To read the entire article in the Volkskrant you need a subscription
11 October 2021
Preserving your own knee joint is the best option for young osteoarthritis patients
“Medical facts” publishes about thesis Sander Hoorntje.
Hoorntje studied the optimal surgical treatment for young, active patients with knee osteoarthritis who would like to sport and work again. Knee osteoarthritis is becoming increasingly common, also with relatively young people. Placing a knee prosthesis in this active group is not desirable, since the risk of failure is high, requiring a second operation. This happens at 1 out-of 3 patients.
Hoorntje’s research shows that joint preserving treatments can be a good first step. There are also treatments in which patients retain their own knee joint. Such as stand correction or the treatment in which the knee joint is put on a small distance for six weeks (knee distraction), with the aim of reducing osteoarthritis complaints. Patients who undergo this treatment often return to sports and work.
A knee replacement operation can also be postponed or prevented. As a result, no costly revision operations are required, which is a favorable outcome for both the patient and society. The stand correction and knee distraction are now relatively rarely performed in the Netherlands; unjustified according to the results of Hoorntje.
5 October 2021
Thesis outcome shows good results ‘return to work’ and ‘return to sport’ after knee distraction
Friday October 1, 2021
Alexander Hoorntje successfully defended his thesis in The Netherlands
Regarding his thesis:
Alexander compared two patient groups on return to sport and return to work. He performed a cross-sectional follow up study in patients <65 years who previously participated in a randomized controlled trial comparing Knee Joint Distraction and high tibial osteotomy.
The outcome of this study showed that the results are comparable. These findings may support further investigation into knee joint distraction as a possible joint-preserving option for challenging “young” osteoarthritis patients.
27 July 2021
First patients treated in KARDS study with the KneeReviver
In Leeds Teaching Hospital two patients were successfully treated with the KneeReviver for a knee joint preserving surgery as start of the KARDS study. ArthroSave has trained orthopaedic surgeons and the theatre staff to use the KneeReviver system. The patients are suffering from severe knee osteoarthritis being too young for a total knee replacement.
The patients were treated on 22 July 2021 in the KARDS study to keep longer their own knee joint while postponing the placement of a first knee replacement. ArthroSave partners with STERIS IMS a provider of reprocessing services facilitating safe and reliable sterile ready delivery of the KneeReviver to the KARDS participating hospitals in the United Kingdom.
Leeds Teaching Hospital is the leader of the KARDS study; Knee ARthroplasty vs Distraction Study (KARDS) is a pragmatic, two-arm NI multi-centre trial designed to establish the clinical & cost-effectiveness of knee joint distraction in a NHS setting. In total 344 patients will be included in two years.
Surgical joint distraction without alignment correction for knee osteoarthritis has gained momentum as an option to delay knee replacement. NICE guidance in this area has found the evidence around this intervention to be lacking in quality and quantity and so has sponsored the KARDS study for further research into this procedure that should lead to future reimbursement. In total 20 hospitals in the United Kingdom are participating in the KARDS study.
13 July 2021
Clinical Trial Knee Distraction funded by Zorginstituut Nederland
With a grant of € 6.7 million from the National Health Care Institute (Zorginstituut Nederland), 14 orthopedic departments of Dutch hospitals are conducting research under the supervision of UMC Utrecht into the (cost) effectiveness of knee distraction. Knee distraction is a promising new joint preserving treatment for patients under the age of 65 with end-stage knee osteoarthritis postponing the total knee replacement for years.
Current clinical research and the recent review of this by the National Health Care Institute showed that treatment with knee distraction for patients younger than 65 years of age is a promising intervention, but at present insufficiently substantiated to be part of reimbursed care. Without reimbursement, such promising treatment for a large population of patients dies a silent death. “With the grant we can now conduct thorough research and demonstrate that the application of knee distraction for the designated target group is really good care,” said study leader, epidemiologist and health technology assessment researcher at UMC Utrecht Paco Welsing.
This is very good news as this means that in 2022-2024 in the Netherlands 600 patients with severe knee osteoarthritis under the age of 65 will be treated with knee distraction and preserving their own knee. We are pleased ArthroSave is fully involved in this study.
For more information (in Dutch):
16 June 2021
ArthroSave in the semi finals of EIT Health Catapult 2021
After pitching in our local regions in May 2021, ArthroSave progressed to the semi-finals of the EIT Health Catapult 2021! The EIT Health Catapult is a training and competition programme that boosts the development of European health start-ups by exposing them to top-quality experts and international investors.
10 June 2021
Extensive study about knee distraction
We kindly present you the result of an extensive study about knee distraction as treatment for painful osteoarthritis of the knee at relatively young patients.
The study was done in the department of rheumatology and immunology at the UMC Utrecht by PhD student Mylène Jansen. It resulted in a beautiful thesis which she will defend at June 15 2021. The research was a joint effort with several orthopedics in the Netherlands and Belgium during the last 3.5 years.
The extensive research gives an insight in the clinical outcome of knee distraction treatment also in comparison with other treatments like high tibial osteotomy and total knee replacement.
During this research, patients treated with ArthroSave’s KneeReviver were also taken into account. PhD student Mylène Jansen did also research at the possible repair of degenerated cartilage and sclerotic subchondral bone during knee distraction.
10 June 2021
ArthroSave is partner at the EFORT – June 30- July 2
If you like to register for this congress, please contact us first. For max 10 applicants we have a 30% discount promo code available.
Find out schedules, presentation titles, names of speakers and abstracts within the 100+ scientific sessions scheduled over the 3 days of the congress. Distinguished guests are Ursula von der Leyen, President of the European Commission, Freddie Fu from the University of Pittsburgh School of Medicine, USA and our Awardees for the EFORT Honorary Award.
10 May 2021
ArthroSave selected for EIT Health Catapult
We want to overcome obstacles to innovation so we can improve healthcare delivery in Europe and make life-changing solutions possible. By working together, we can remove barriers across borders to create a more resilient and dynamic European healthcare system.
10 May 2021
ArthroSave selected by the EIT Bridgehead program
Four Dutch healthcare start-ups have been selected in the EIT Health Bridgehead 2021 program!
ArthroSave is among them.
We will receive support in reaching markets in Europe and beyond, to plan how to access new markets quickly and decisively, tap into local networks of partners and clients, access infrastructure and understand new regulatory systems. ArthroSave will mainly focus on UK and BRD for this fantastic program.
7 May 2021
Joint distraction versus osteotomy
ESSKA, 2021 Congress
Very informative speech of Prof. Dr. Floris Lafeber regarding Joint Distraction versus osteotomy.
You can join this virtual speech at May 14, 13.06- 13.12 hour.
Mr. Lafeber explains about the latest insights regarding the comparison of Joint Distraction and Osteotomy.
For many patients and professionals this presentation gives you up to date information which helps you to decide if our treatment with KneeReviver might be taken in consideration.
25 February 2021
ArthroSave supports this year’s winners of ASC 2020
As winner of the Academic Startup Competition in 2019 we share our knowledge and experience to the winners of 2020 to help them building and structuring their start-up. As alumni we do support this competition being an ambassador .
Click here for: Tips and tricks on pitching in a Digital Mission.
1 January 2021
Clinical study Knee Joint Distraction will start in the UK in 2021
In the UK a clinical study for patients with severe knee osteoarthritis will start. In this study the clinical and cost-effectiveness of Knee Joint Distraction will be compared to Knee Arthoplasty.
The study will start in 2021 in twenty hospitals and will be coordinated by the University of Leeds. The study has been funded by the NHS and will lead to reimbursement when the results are positive.
6 August 2020
Article in German magazine Arthroskopie
The German magazine Arthroskopie has published an informative article about knee joint distraction with the title ‘Knee joint distraction in the treatment of severe osteoarthritis’. References to the scientific background are included.
19 March 2020
Digital fundraising for ReumaNL
ReumaNL decided to cancel the door-to-door ‘collecteweek’ due to the outbreak of the COVID-19 virus. Therefore it is now possible to make your own digital ‘collectebus’ . Hopefully ReumaNL will receive a lot of donations this way!
It is also possible to share the donation-call via Facebook, you and your friends can donate via a ‘Tikkie’.
24 January 2020
ArthroSave present at annual NOV congress 30-31 January 2020
Next week ArthroSave will be present at the NOV congress in ‘s-Hertogenbosch – The Netherlands. We hope to meet you at our booth, to discuss the advantages of knee joint distraction treatment with the KneeReviver.
18 January 2020
ArthroSave’s CEO about the KneeReviver in Financieel Dagblad
Every week in section “De Vonk” of the “Financieel Dagblad” somebody tells about a decisive moment in their career. This week ArthroSave’s CEO Karianne Lindenhovius. About the development of the KneeReviver and how this can postpone a knee replacement for some years. Read the article.
19 December 2019
ArthroSave’s KneeReviver highlighted in ‘de Barometer’ on RTLZ
‘De Barometer’ is a TV show hosted on national Dutch television by RTLZ, and they bring an item about Pontes Medical and ArthroSave. Pontes Medical is a valorization initiative, applied for over 10 years now in the UMC Utrecht and Amsterdam UMC, and ArthroSave arose from this approach. During this show, new innovation methods for medical devices are discussed, of which the KneeReviver is one success story.
1 November 2019
ArthroSave’s (female) CEO nominated for VIVA400 award
We are proud to share that Karianne is nominated for the VIVA400 award in the category ‘Zorgdragers’. The VIVA400 list is composed of women who excel in their workfield and forms a platform and network for ambitious and entrepreneurial women. They are a great inspiration for others through what they do, through the successes they have achieved and through what they want to achieve (even more). Nominated women are successful women who matter and make the difference. The awards are presented on December 12th.
23 October 2019
Learn how to use the KneeReviver at the Utrecht Joint Preserving Course 1-2 November 2019
The first weekend of November dr. Roel Custers and dr. Nienke van Egmond organise the first Utrecht Joint Preserving Course. On Friday presentations are given about knee joint distraction treatment and on Saturday we provide a hands-on kadaveric course how to use the KneeReviver for knee joint distraction treatment.
17 October 2019
ArthroSave present at the CESunveiled Amsterdam 2019
We are proud that we, a spin-off of the UMC Utrecht and Pontes Medical, can translate our academic knowledge into better medical care and strengthening the economy.
12 October 2019
ArthroSave shows the KneeReviver at Rond Reuma Live 2019
At the 12th of October we performed a showcase at the Rond Reuma Live patients convention. We showed our KneeReviver device and told patients all they need to know about knee joint distraction treatment.
16 September 2019
ArthroSave with US Holland in the Valley 2019
Last September, our CEO and CSO went to an Incubator programme in Sillicon Valley following the win of the Academic Startup Competition. They were hosted by Gigi Wang and the Consulate General of the Netherlands in San Francisco, Walter van der Weiden, and made great connections in the field of regulatory, reimbursement, marketing, entrepreneurship and investment. In the second week they were hosted by @FocusInnovationStudioSF and have had indepth meetings with clinicians, hospitals and FDA experts.
21 May 2019
ArthroSave wins Academic Start-up Competition
The Academic Startup Competition is an initiative of VSNU, the Netherlands Academy of Technology and Innovation (AcTI) and StartupDelta. The competition put knowledge transfer and academic spin-offs in the international spotlight.
As a result of the selection, ArthroSave will be able to pitch at the Global Entrepreneurship Summit (GES) and will be offered a trip to Silicon Valley by the Ministry of Economic Affairs and Climate Change. The GES will give ArthroSave the opportunity to learn how to scale up their innovation faster and take the step from startup to scale-up.
11 February 2019
KneeReviver at Annatommie mc Amsterdam-Amstelveen
On the 11th of February an article (Dutch) was published on the website of Annatommie mc in which Dr van Rhee explains the treatment.
1 February 2019
Knee joint distraction in national paper Volkskrant
On the 1rst of February an article (Dutch) was published in the national paper Volkskrant in which Prof Lafeber and Dr Custers explains knee joint distraction.
23 November 2018
KneeReviver in national paper
On the 23rd of November an article (Dutch) was published in the national Dutch paper AD in which Dr Spruijt explains knee distraction and the advantages of this technique. Importantly, this technique is now also available in the Haga Hospital (photo by © NICO SCHOUTEN) in which Dr Spruijt works.
15 October 2018
Joint distraction in national regional news
On the 15th of October an article (Dutch) was published in the national regional news website of RTVNoord. The Martini Ziekenhuis in Groningen is the first hospital in the region North Holland to offer knee joint distraction.
1 October 2018
Joint distraction in UMC news
On the 1st of October an article (Dutch) was published on the UMC Utrecht webpage. UMC Utrecht has treated the first patients in regular care which is another milestone of this treatment.
26 September 2018
First patient-meeting with knee joint distraction as theme
On the 26th of September a succesful patient-meeting was held at the UMC Utrecht specifically focussing on knee joint distraction. The program, organised by the Rheumatology and Orthopedic departments of the UMC Utrecht, consisted of an update of the current scientific status of the treatment and a discussion to receive patient input on new research. Moreover, it was discussed whether it would be useful to set-up a patient organisation/network specifically for patients treated or interested in joint distraction. Dr Custers, Prof Lafeber, Dr Jansen and Dr Mastbergen presented the latest results and future work on knee joint distraction. Dr Oosterwijk presented on the possibilities for patient organisation The evening was characterised by a lively discussion between the presenters and the patients and resulted in valuable input for future presenters. Over 50 patients attended the evening.
18 September 2018
First patient treated with the KneeReviver at Annatommie mc
On the 18th of September, for the first time the knee Reviver was used to treat a OA patient with knee joint distraction at Annatommie mc. This is a new milestone and indicates a growing amount of hospitals using this system in the Netherlands.
6 September 2018
Joint distraction presented at the 5th Joint Preservation congres at Warsaw
On 6-8 September the 5th Joint Preservation congres was held at Warsaw Poland. Prof Lafeber and Dr Mastbergen were invited to present in a dedicated session entitled “Joint distraction as joint preserving treatment”.
9 April 2018
Joint distraction highlighted in newspaper article
To promote innovation prince Constantijn, who is an ambassador of innovative companies in the Netherlands, visited de ‘StartupDelta Summit’ on Industriepark Kleefse Waard. Also joint distraction and the knee reviver was presented by our CEO Karianne Lindenhovius.
7 April 2018
Joint distraction highlighted in UMC Utrecht UREKA Mega Challenge
To promote the UMC Utrecht UREKA Mega Challenge, a innovation gameshow, the knee reviver was chosen as lead on the posters around the UMC. The engineer and orthopaedic surgeon, both valuable academic team-members are holding the Knee reviver.
14 June 2017
Joint distraction highlighted EULAR 70th Anniversary
To mark its 70th Anniversary, EULAR has documented its history and contribution to rheumatology in an anniversary timeline presented at large billboards during the annual meeting of EULAR 2017 at Madrid, Spain. Joint distraction was included as novel surgery in this timeline.
18 November 2016
90 jaar Reumafonds documentary
Orthopedic surgeon Dr Custers explains the joint distraction treatment in the short documentary of innovations of importance to the patient made by the Dutch Arthritis Foundation as part of their 90th anniversary. The distraction specific part begins around 8.00 minutes.
(documentary is in Dutch)
15 November 2016
Arthosave participaties in large STW project
A large grant is awarded by the Dutch Technology Foundation STW to the project entitled “William Hunter Revisited: Activating intrinsic cartilage repair to restore joint homeostasis” in which ArthoSave participates to study the mechanisms behind intrinsic cartilage repair as seen with joint distraction. ArthroSave, together with the UMC Utrecht and University Utrecht, will specifically focus on early changes in joint tissues as induced by joint distraction.
11 November 2016
Presentation ‘let’s frame it’ Floris Lafeber
On 11 Novemebr 2016 Professor Lafeber gave a TED-like presentation, being 1 of the 25 invited speakers, on the special conference “Verder in Beweging” to celebrate the 80th anniversary of the Sint Maartenskliniek Nijmegen. This clinic is one of the early adaptors of the joint distraction treatment in the trials performed in collaboration with the UMC Utrecht.
(presentation is in Dutch)
13 October 2015
Joint distraction on national television
On 13 October 2015 the popular program “Tijd voor Max” on National Public Television aired an item dedicated to joint distraction as treatment for osteoarthritis patients. The General Practitioner Dr Ted explains osteoarthritis and why joint distraction can be a good solution for the young patient.
(video is in Dutch)